Companies › Hangzhou Converd
1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| hV01 Recombinant vaccinia virus with deletions of viral thymidine kinase (TK) and viral growth | IL21 | Phase 2 | Advanced Pancreatic Cancer; Advanced Solid Tumors | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05914376 | hV01 | Phase 1 | Advanced Solid Tumors | Oncology | Jun 2027 |
| NCT07006077 | hV01 | Phase 2 | Advanced Pancreatic Cancer | Oncology | Dec 2028 |
–
Abscint NV/SA Beijing Gene Key Life Technology CNBG-Virogin Biotech (Shanghai) Stella Pharma Dendreon
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.